



NDA 21-130/S-035
NDA 21-131/S-029
NDA 21-132/S-034

SUPPLEMENT APPROVALS

Pharmacia & Upjohn Company
a subsidiary of Pfizer, Inc.
Attention: Nadia D. Kirzecky
Director, Worldwide Safety and Regulatory
235 East 42nd Street
New York, NY 10017

Dear Ms. Kirzecky:

Please refer to your Supplemental New Drug Applications (sNDAs) dated May 5, 2015, received, May 5, 2015, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

- Zyvox (linezolid) Tablets, 600 mg (NDA 21-130)
- Zyvox (linezolid) Injection, 200, 400 and 600 mg (NDA 21-131)
- Zyvox (linezolid) Oral Suspension, 100 mg/5 mL (NDA 21-132)

We acknowledge receipt of your amendments dated June 4, 2015.

These supplemental applications provide for revisions to Subsection **12.4, Microbiology** and Subsection **14.2, Pediatric Patients, Infections due to Gram-positive Bacteria**, in response to the Prior Approval Supplement request letter dated March 5, 2015. In addition, Section **15, REFERENCES**, has been updated and minor editorial revisions have been made.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended and they are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revision listed below and included in the enclosed labeling:

- Replacement of “<” symbols in **HIGHLIGHTS** and Table 1 with the designation “less than”

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 21-130/S-035
NDA 21-131/S-029
NDA 21-132/S-034
Page 3

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
06/05/2015